• Prilocaine: Mechanism, Identity and Evidence Scope

  2026-10-16

  APExBIO identifies Prilocaine, or 2-(propylamino)-N-(o-tolyl)propanamide, as an amino amide local anesthetic and sodium channel blocker. Its product documentation supports a conceptual link between neuronal sodium-channel inhibition and reduced nerve impulse conduction, but it does not provide identity-matched study data, quantitative outcomes, or comparative evidence.

• IMP (M1405): What the Record Supports

  2026-10-15

  The linked APExBIO product page identifies IMP by catalog number M1405, but the available product information does not establish a chemical identity, mechanism, measurement principle, or research-supported performance claim. The defensible interpretation is therefore limited to catalog-level identification and explicit evidence boundaries.

• HEK293 Cells: What the Product Record Supports

  2026-10-15

  The APExBIO listing identifies HEK293 Cells under SKU BC1010, but the available product information provides no description, mechanism, assay readout, validation data, or identity-matched study. The evidence therefore supports a catalog-level identity only, not conclusions about biological performance or experimental suitability.

• ANGPTL3 sgRNA Product: Evidence and Scope

  2026-10-14

  The APExBIO catalog record identifies R2999 as three preparations of sgRNA described as targeting the human ANGPTL3 gene, with 3 µmol listed for each component. The record does not provide sequences, nuclease context, delivery information, validation data, or a matched research publication. Accordingly, the product can be discussed as a target-designation and reagent-identity claim, not as evidence of editing performance or biological effect.

• Sultamicillin Tosylate: Identity and Evidence Scope

  2026-10-14

  Sultamicillin Tosylate is described by APExBIO as a tosylate salt and chemically synthesized mutual prodrug of ampicillin and sulbactam. With no matched research paper available, the evidence supports discussion of product identity and conceptual relevance to antibacterial research, but not independent claims about efficacy, mechanism, or clinical applicability.

• E-64 and the Evidence for Lysoptosis

  2026-10-13

  Existing evidence supports lysoptosis as a cathepsin-dependent lysosomal death program in selected genetic and epithelial models, but it does not establish that E-64 was used in the defining comparison or that pharmacological cysteine protease inhibition alone identifies this pathway. The main evidence gaps concern pathway specificity, cross-model reproducibility, and translation beyond the studied systems.

• Tunicamycin and ER Stress: Evidence in Context

  2026-10-13

  Tunicamycin is described by APExBIO as a N-glycosylation inhibitor and endoplasmic reticulum stress inducer. The supplied hepatitis C virus study used tunicamycin as a comparative ER-stress model while primarily investigating whether naringenin modulates IRE1α–XBP1 signaling and hepatic insulin resistance. The findings support a mechanistic association, but they do not establish clinical efficacy or validate tunicamycin as a treatment.

• Procainamide and Cisplatin in Pregnant Mice

  2026-10-12

  A 2006 mouse study examined whether procainamide hydrochloride could accompany cisplatin without worsening embryotoxicity. The findings suggest no additional embryotoxic signal in the tested model and modest improvements in selected fetal endpoints, but they do not establish clinical safety, efficacy, or applicability to human pregnancy.

• HNF4A-AS1 and Sorafenib Resistance in HCC

  2026-10-12

  The 2024 Theranostics study links reduced HNF4A-AS1 with sorafenib resistance and altered lipid metabolism in hepatocellular carcinoma models. Its multi-model findings support a mechanistic hypothesis involving m6A regulation, DECR1, polyunsaturated fatty acids, and ferroptosis, but they do not establish clinical utility or show that glucose uptake caused the reported phenotype. The 2-NBDG Glucose Uptake Assay Kit is a separate fluorescent glucose-uptake product whose documented scope should not be conflated with the study’s lipid-metabolism evidence.

• Cytochalasin B: Evidence, Context, and Limits

  2026-10-11

  Cytochalasin B is presented as an actin-directed cytoskeletal research tool, but the supplied heat-not-burn toxicology study does not evaluate Cytochalasin B or actin biology. Its findings support only a product-specific, endpoint-limited comparison and do not establish clinical safety or broader toxicological conclusions.

• SARS-CoV-2 NSP15 Screening: Thymopentin and Oleuropein

  2026-10-10

  A 2021 structure-based study screened a natural-product library against the SARS-CoV-2 NSP15 endoribonuclease and identified thymopentin and oleuropein as the strongest predicted binders. Molecular dynamics supported persistence of the modeled complexes, but the findings remain computational and require biochemical, cellular, and in vivo validation before antiviral activity can be inferred.

• TUNEL Apoptosis Detection Kit: Evidence and Limits

  2026-10-09

  The TUNEL Apoptosis Detection Kit supports DNA fragmentation detection in apoptosis through a TdT–biotin–streptavidin-HRP signal system with DAB visualization. It is useful for tissue sections and cultured cells, but a TUNEL-positive signal does not independently establish apoptosis or disease mechanism.

• Rosiglitazone and Variant-Aware PPARγ Research

  2026-10-09

  Rosiglitazone is more than a reference PPARγ agonist: it can help distinguish ligand responsiveness from receptor instability in metabolic research. This article interprets the PPARG R212W study, explains its evidence limits, and develops a genotype-aware framework for studying adipocyte dysfunction.

• Clozapine N-oxide in Circuit Neuroscience

  2026-10-08

  Clozapine N-oxide (CNO) is widely associated with DREADD-based chemogenetics, but its interpretation requires pharmacological caution. This overview examines its research context, the reported exercise–depression circuit findings in a doctoral thesis, the contrast between chemogenetic and optogenetic evidence, and limitations affecting translation from male-mouse models to human neuroscience.

• Sulfisomidine in Pertussis: Findings and Limits

  2026-10-08

  The 1956 report on sulfisomidine in pertussis combined clinical observation with serial blood and urine measurements, offering an early pharmacokinetic and safety perspective in a small pediatric case series. Its findings support historical feasibility and describe drug exposure, but the combined treatment design and lack of a comparator limit conclusions about efficacy or present-day clinical use.

8568 records 1/572 page Next 12345 下5页 Last page